Japan's pharma market grows 7.7%
With no negative impact of National Health Insurance drug price revisions, Japan’s ethical pharmaceutical market has seen growth for three quarters running, increasing 7.7% year-on-year in the third quarter of 2011 to a value of 2,332.26 billion yen ($29.92 billion), according to top-line figures released by IMS Japan.
Within the overall figures, the hospital market (medical institutions with more than 100 beds) expanded 6.3% to 920.49 billion yen, while the GP market (medical institutions with less than 100 beds) was worth 572.61 billion yen a leap of 9.7%.
Top therapy classes and brands
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze